Alligator Bioscience announces that an investigator-initiated randomized phase II/III study will evaluate mitazalimab in combination with the chemotherapy FOLFOX in patients with previously treated biliary tract cancer. The study is led by Prof. Cindy Neuzillet and Dr. Matthieu Delaye vid Institut Curie w/ Unicancer as sponsor. The first patient is expected to be recruited in the second quarter of 2026 and the initial part of the study is planned to include 112 patients at 30 clinics in France.
|
Published September 8, 2025
New phase II/III study with Alligator's mitazalimab
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account